Maiden Biosciences, Inc., a collagen-based wound care company, proudly celebrates nearly a decade of innovation and dedication to supporting patients and healthcare providers in managing a range of wounds. Founded by entrepreneur Mark Gorman, the company has grown from a bold startup into a respected presence in the prescription-based wound care market.
Sourced by Maiden Biosciences, Inc.
From its inception, Maiden Biosciences has centered on addressing a segment of healthcare that focuses on the management of wounds associated with diabetes, obesity, aging, surgical procedures, and other medical conditions. Its core products include a collagen sheet and a powdered collagen dressing, both designed to create optimal conditions for wound healing. Additionally, the company is actively developing multiple projects, signaling its ongoing commitment to advancing regenerative medicine.
Collagen Sheets and Collagen Powder (Source: Maiden Biosciences, Inc.)
“Wound care is an underserved market, and the need has always been clear to me,” says Gorman. “I started this company because I saw an opportunity to make a difference while building a sustainable business. Our goal is to provide healthcare providers with safe, versatile products that can support the management of wounds in a wide range of patients.”
Maiden Biosciences’ products are uniquely designed for moderate to deeply exudative wounds, helping maintain ideal conditions for wound management. The products are also indicated to help control minor bleeding. The company’s bovine collagen dressings have been observed to support patient comfort, potentially reducing pain, minimizing scarring, and allowing for fewer dressing changes, enhancing overall patient management.
Sourced and manufactured in the US, Maiden Biosciences ensures quality, safety, and regulatory compliance. The products feature a shelf life of 5–10 years, which could offer healthcare providers a reliable and long-lasting solution. Designed to meet the criteria for wound management, these products can be considered in place of more advanced treatments, while continuing to align with standard clinical practices. “Virtually any wound at any stage of healing can be considered for our products,” Gorman explains. “Physicians appreciate that they can integrate our collagen sheets or powders into their existing treatment plans without changing what they already do. The approach is simple: clean the wound, apply collagen, and cover it, adding an organic layer that works with the body’s natural processes.”
Before founding Maiden Biosciences, Gorman spent years in banking and later shifted into the bioscience industry. Drawing from his entrepreneurial background and hands-on experience in wound care, he recognized an opportunity to offer physicians and patients something distinctive. “It’s rewarding to be in a business where we help patients while building a sustainable company. Our products are straightforward, safe, and built from a natural component of the skin, collagen,” he adds. Looking ahead, Maiden Biosciences remains committed to innovation, exploring new products and applications that extend its mission of supporting patients and healthcare providers. The company is open to partnerships and funding opportunities that align with its vision of expanding access to advanced wound care solutions.
As Maiden Biosciences celebrates this milestone, it underscores a journey driven by entrepreneurial vision, patient-centered innovation, and a commitment to an often-overlooked market. With a foundation rooted in science and a focus on real-world healthcare challenges, the company continues to shape the future of wound care.
A medical disclaimer states that the information provided is not a substitute for professional medical advice and that users should consult a healthcare professional for any health concerns
Media Contact
Name: Mark Gorman
Email: [email protected]
